														CIC	MC	S F	O	RN			
SUSPECT ADVERSE REACTION REPORT																					
							П			Ι	Π	T	Т		Τ	Τ	I	Τ			
															L						
				INFORM		_					1.										
1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY DOMINICAN REPUBLIC	Day Month Year PRIVACY	2a. AGE 8 Years	3. SEX Female	3. SEX 3a. WEIGHT 4-6 REACTION ONSET 8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION ONSET 0-1 ADVERSE REACTION																
Event Verbatim [LOWER		t tests/lab data) mptoms if any separated by comm air [Device physical pro	-	sue]							֓֟֝֟֝֟֝֟֓֓֓֓֓֓֓֓֟֟֝֓֓֓֓֓֓֓֟֡֟֝	ш		ENT DIE							
Case Description: This is a spontaneous report received from a Const quality group, Program ID: 164974.				nsumer or o	umer or other non HCP from product							PROLONGED INPATIENT HOSPITALISATION									
An 8-year-old female patient received somatropin (GENOTROPIN PE mg daily (2.0 mg, daily (every night)).					EN), (Batch/Lot number: unknown) at 2								INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY								
(Continued on Addition							al In	format	ion P	age	, 1		LIFE THRI	EATENI	NG						
		II. SUSPEC	T DRU	IG(S) INF	ORMA	TIO	N														
SUSPECT DRUG(S) (include generic name) #1) Genotropin Pen (SOMATROPIN) Solution for injection #2) Genotropin Pen (SOMATROPIN (DEVICE CONSTITUENT)) Solution f					for injection									20. DID REACTION ABATE AFTER STOPPING DRUG?							
15. DAILY DOSE(S) #1) 2.0 mg, daily (every night) #2)				#1) Unknov	: ROUTE(S) OF ADMINISTRATION 1) Unknown 2) Unknown								YES NO NA								
17. INDICATION(S) FOR USE #1) Unknown #2) Unknown													21. DID REACTION REAPPEAR AFTER REINTRODUCTION?								
#1) Unknown				#1) Unknov	. THERAPY DURATION) Unknown 2) Unknown								YES NO NA								
		III. CONCOMIT	TANT D	RUG(S)	AND H	IST	OR'	Y													
22. CONCOMITANT DRU	JG(S) AND DATES OF ADM	MINISTRATION (exclude those use	ed to treat re	eaction)																	
23. OTHER RELEVANT From/To Dates Unknown	HISTORY. (e.g. diagnostics,	allergies, pregnancy with last mo Type of History / Notes	onth of period	d, etc.) Description																	
Olikilowii																					
		IV. MANUF	ACTU	RER INF	ORMAT	ΓΙΟΝ	1														
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A.				26. REM	ARKS																
Laura Arce Mora Avenida Escazú, T San Jose, COST	orre Lexus, piso 7. E A RICA	Escazú																			
	24b. MFR CC	ONTROL NO.		25h NAN	IE AND ADD	RESS C	FRF	PORTE	R												
	PV20250		25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																		
24c. DATE RECEIVED BY MANUFACTURE	24d. REPORT	T SOURCE		NAME	AND ADD	RES	S W	ITHHE	ELD.												
20-AUG-2025	HEALTH	ш	aneous																		
DATE OF THIS REPORT 25-AUG-2025	25a. REPOR	T TYPE																			

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: DEVICE PHYSICAL PROPERTY ISSUE (non-serious), outcome "unknown", described as "the vial always ends up with a lot of air".

Causality for "the vial always ends up with a lot of air" was determined associated to device constituent of somatropin (malfunction).

Additional information: The patient's caregiver stated: 'I've been having problems with the medication Genotropin for several months. When I insert the hormone, the vial always ends up with a lot of air. They've already replaced the pen twice, and the same issue keeps happening. The pen that lasted the longest was the last one they gave me. The girl at the place where I pick up the medication told me to contact you to check if there's a manufacturing issue with the medication, or if the device could be replaced, because they don't have any available at the location.

Product Quality Group provided investigational results on 20Aug2025 for somatropin (device constituent): Investigation Summary and Conclusion: Site investigation (Pfizer Manufacturing Site): No further investigation was required as no valid lot number or returned sample was available. This complaint will continue to be trended. If additional information becomes available, this complaint will be reopened. Device Investigation: This investigation is based on the information captured in the Complaint Description and Argus Report. The Complaint Issue, Cannot Remove Air, was reported. The Risk Management File was reviewed to confirm that the Hazard(s) and Hazardous Situation(s) associated with the Complaint Issue are documented in the Hazard Analysis (INX#100281795, Version # (9.0)). All complaint investigations are trended. There is no current trend alert documented.

Causality for "the vial always ends up with a lot of air" was determined associated to device constituent of somatropin (malfunction).

The information on the batch/lot number for somatropin will be requested and submitted if and when received.

Follow-up (20Aug2025): This is a spontaneous follow-up report from product quality group providing investigation results. Updated information: event details ((Event "Device chemical property issue" recoded to "Device physical property issue") and investigation results.